What was studied?
This interim analysis covered 248 adults with overweight or obesity randomized at 20 hospitals in China. The primary assessment was weight change at 24 weeks.
What did the researchers report?
The mazdutide groups had greater average weight reduction than placebo. Diarrhea, nausea and upper respiratory tract infection were among the reported adverse events.
What are the limits?
The analysis concerns selected study groups and a short follow-up. Population characteristics and trial-specific eligibility matter when considering applicability elsewhere; the result is not evidence for every marketed material carrying the same name.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.